Human Microbiome

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state and likely evolution of microbiome therapeutics, diagnostics and FMT therapies market in the short-mid term and long term.

Chapter 3 provides a general overview of human microbiome, concepts pertaining to microbiota and microbiome, a discussion on the role of resident microorganisms in disease development (particularly for conditions caused by an imbalance in the microbiome) and in certain cases, prevention. It presents an elaborate assessment on various functions of the microbiota, emphasizing on the key aspects of the Human Microbiome Project (HMP). Further, the chapter describes the various types of microbiome therapeutics, such as probiotics and prebiotic drugs, which are available / under development. It also provides an overview of the regulatory requirements for live biotherapeutic products (LBPs), in addition to highlighting the challenges associated with the development of microbiome therapeutics.

Chapter 4 includes detailed assessment of the current market landscape of microbiome therapeutics, providing information on preclinical and clinical drugs along with information on clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, prescription drug and vaccine), target indication(s), therapeutic area(s), route of administration, type of drug formulation, type of therapy (monotherapy and combination therapy), combination drug (in case of combination therapies), dosing frequency (reported for clinical candidates only), and special drug designations (if any). In addition, the chapter provides details on the companies engaged in the development of microbiome therapeutics, along with information on their year of establishment, company size and location of headquarters.

Chapter 5 features detailed profiles of key players engaged in the development of microbiome therapeutics (which are presently in phase III clinical trials); each profile features a brief overview of the company, its financial information (if available), microbiome-based drug portfolio, information on clinical trial (featuring, current status of development and phase III clinical trial information) and an informed future outlook. In addition, the chapter also features profiles of the players engaged in more than six therapeutic programs, along with a company overview, financial information (if available), drug portfolio and an informed future outlook. 

Chapter 6 features an analysis on various types of diagnostic and screening / profiling tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with detailed review of the current market landscape of microbiome diagnostic and screening / profiling tests, including the information on stage of development (commercialized and under development), type of sample analyzed (blood, feces, saliva and vaginal swab), type of screening technique (gene sequencing, PCR, microarray, ELISA, DNA analysis, drug metabolites and others) target indication(s), key therapeutic area(s) and purpose of diagnosis. The chapter also features information on the diagnostics and screening / profiling test providers(s) along with information on their year of establishment, company size and location of headquarters.

Chapter 7 presents elaborate profiles of key players engaged in the development of microbiome diagnostics and screening / profiling tests. Each profile features a brief overview of the company, its financial information (if available), diagnostic or screening / profiling test portfolio, recent developments and an informed future outlook.

Chapter 8 presents review of the historical evolution and other relevant aspects of FMT, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with detailed assessment of the current market landscape of FMT, providing information on various parameters of FMT such as,  the status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration. In addition, the chapter includes information on FMT provider(s), along with information on their year of establishment, company size and location of headquarters.

Chapter 9 highlights a detailed analysis of completed and ongoing clinical trials of FMT, based on different parameters, such as trial status, trial registration year, trial phase, year-wise trend of completed and recruiting trials, study design, number of patients enrolled. In addition, the chapter highlights, age category of the patients enrolled, type of sponsor / collaborator, active industry and non-industry players and location of the trials. Furthermore, the chapter also features information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.

Chapter 10 features an insightful business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.

Chapter 11 presents the detailed analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s).

Chapter 12 presents an assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.

Chapter 13 presents analysis of the partnerships that have been established since 2017, covering various parameters such as, research and development, clinical trials agreement, merger / acquisition, product development and commercialization agreement and product development and manufacturing agreement of the companies focused on developing microbiome-based therapeutics, diagnostics and FMTs.

Chapter 14 presents a detailed analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.

Chapter 15 features an elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, type of product manufactured and type of formulation. In addition, the chapter highlights key consideration for selecting a CMO / CRO partner.

Chapter 16 presents an assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade. The chapter also features a list of companies offering big data-related services / tools to support microbiome research, and brief profiles of some of the popular companies that are engaged in this field of research.

Chapter 17 features an elaborate market forecast analysis, highlighting the future potential of microbiome therapeutics till 2035. Based on an informed top-down approach, taking into account current and projected performance of the microbiome therapeutics market, it features the likely distribution of the current and forecasted opportunity across type of product (probiotic and other drugs), target indication (graft versus host disease, necrotizing enterocolitis, primary hyperoxaluria and recurrent CDI), therapeutic area (digestive and gastrointestinal disorders, infectious diseases and rare disorders), route of administration (oral and rectal), type of formulation (capsules, suspensions and enemas), key geographical regions (North America, Europe, Asia-Pacific),  leading drug developers, and leading therapeutic products. The potential sales forecast of the therapeutic products that are in the later stages of development (phase III) is based on multiple relevant parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the late-stage drugs and likely selling price. 

Chapter 18 features a detailed market forecast analysis, highlighting the future potential of microbiome-based diagnostic tests till 2035. Based on multiple parameters, such as target consumer segments, disease prevalence, anticipated adoption of diagnostic tests and price, the analysis provides an informed opinion on the likely distribution of the current and forecasted opportunity across  target indication (colorectal cancer, diabetes mellitus, inflammatory bowel disease and irritable bowel syndrome), therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncological disorders) and  key geographical regions (North America, Europe, Asia-Pacific). It is worth mentioning that a bottom-up approach was adopted for this analysis, wherein our estimates of the likely size of the microbiome-based diagnostics market were validated using relevant datapoints and inputs from primary research. The chapter features market projections both in terms of value (USD million) and volume (number of diagnostic tests). 

Chapter 19 features an informed market forecast analysis, highlighting the future opportunity within the FMT market till 2035, based on parameters, such as the average number of FMT procedures conducted in a year and average cost of approved FMT. It is worth mentioning that the chapter features market projections both in terms of value (USD million) and volume (number of procedures). 

Chapter 20 is a case study on various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over the counter (OTC) products that are being used as dietary supplements.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinions related to the research and analysis described in the previous chapters.

Chapter 22 consists of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Charlie Badham (Senior Manager, Corporate Development, 4D Pharma), Nicholas Monsul (Co-founder and Chairman, Quorum Innovations), Alicia Scheffer (Chief Executive Officer, Floragraph), Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories), Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Assaf Oron (Chief Business Officer, BiomX), Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics), Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics), James Burges (Ex-Co-founder and Vice President of Innovation, OpenBiome), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics), JP Benya (Ex-Vice President, Operations, Assembly Biosciences), Lee Jones (President and Chief Executive Officer, Rebiotix), Mark Heiman (Ex-Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics) and Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra).

Chapter 23 is an appendix, that contains the tabulated data and numbers for all the figures in the report.

Chapter 24 is an appendix, that provides the list of companies and organizations mentioned in the report. 

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.2.1. Discovery of the Human Microbiome
3.2.2. Functions of the Human Microbiome

3.3. Overview of Gut Flora
3.3.1. Role of Gut Flora in Human Health
3.3.2. Factors Affecting Gut Flora
3.3.2.1. Antibiotic Consumption
3.3.2.2. Age and Pregnancy
3.3.2.2.1. Mode of Childbirth
3.3.2.2.2. Type of Feeding
3.3.2.2.3. Antibiotic Consumption by Mother
3.3.2.3. Stress-related Factors
3.3.2.4. Dietary Factors
3.3.2.5. Impact of Lifestyle

3.4. The Microbiome and Associated Diseases
3.4.1. Cancer
3.4.2. Inflammatory Bowel Disease (IBD)
3.4.3. Obesity
3.4.4. Parkinson’s Disease
3.4.5. Type 2 Diabetes
3.4.6. Other Disease Indications

3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes

3.7. Microbiome Therapeutics
3.7.1. Probiotics
3.7.1.1. Beneficial Bacterial Strains
3.7.1.1.1. Lactobacilli
3.7.1.1.2. Bifidobacteria
3.7.1.1.3. Others

3.7.1.2. Key Therapeutic Areas
3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
3.7.1.2.2. Bacterial Vaginosis
3.7.1.2.3. High Blood Pressure
3.7.1.2.4. Hypercholesterolemia
3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
3.7.1.2.6. Inflammatory Bowel Disease (IBD)
3.7.1.2.7. Lactose Intolerance
3.7.1.2.8. Vitamin Production
3.7.1.2.9. Weight Management

3.7.1.3. Side Effects of Probiotics

3.7.2. Prebiotics
3.7.2.1. Sources of Prebiotics
3.7.2.2. Types of Prebiotics
3.7.2.2.1. Fructo-Oligosaccharides (FOS)
3.7.2.2.2. Galacto-Oligosaccharides (GOS)
3.7.2.2.3. Inulin

3.7.2.3. Key Therapeutic Areas
3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
3.7.2.3.2. Constipation
3.7.2.3.3. Gastrointestinal Diseases
3.7.2.3.4. Dysbiosis
3.7.2.4. Side Effects of Prebiotics

3.8. The Human Microbiome Project (HMP)
3.8.1. Project Approach
3.8.2. Project Initiatives
3.8.3. Project Achievements

3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development and Type of Molecule
4.2.4. Analysis by Type of Biologic
4.2.5. Analysis by Type of Product
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Dose Frequency
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Combination Drug

4.3. Microbiome Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Phase of Development and Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Product
4.3.6. Analysis by Target Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Route of Administration

4.4. Microbiome Therapeutics: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
5.3. Finch Therapeutics
5.3.1. Company Overview
5.3.2. Microbiome-Based Product Portfolio
5.3.2.1. CP101
5.3.2.1.1. Drug Overview
5.3.2.1.2. Current Status of Development
5.3.2.1.3. Clinical Studies
5.3.3. Recent Developments and Future Outlook

5.4. Infant Bacterial Therapeutics
5.4.1. Company Overview
5.4.2. Microbiome-Based Product Portfolio
5.4.2.1. IBP-9414
5.4.2.1.1. Drug Overview
5.4.2.1.2. Current Status of Development
5.4.2.1.3. Clinical Studies
5.4.3. Recent Developments and Future Outlook

5.5. MaaT Pharma
5.5.1. Company Overview
5.5.2. Microbiome-Based Product Portfolio
5.5.2.1. MaaT013
5.5.2.1.1. Drug Overview
5.5.2.1.2. Current Status of Development
5.5.2.1.3. Clinical Studies
5.5.3. Recent Developments and Future Outlook

5.6.1 OxThera
5.6.1. Company Overview
5.6.2. Microbiome-Based Product Portfolio
5.6.2.1. Oxabact
5.6.2.1.1. Drug Overview
5.6.2.1.2. Current Status of Development
5.6.2.1.3. Clinical Studies
5.6.3. Recent Developments and Future Outlook

5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Microbiome-Based Product Portfolio
5.7.3.1. RBX2660
5.7.3.1.1. Drug Overview
5.7.3.1.2. Current Status of Development
5.7.3.1.3. Clinical Studies
5.7.4. Recent Developments and Future Outlook

5.8. Seres Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Microbiome-Based Product Portfolio
5.8.3.1. SER-109
5.8.3.1.1. Drug Overview
5.8.3.1.2. Current Status of Development
5.8.3.1.3. Clinical Studies
5.8.3.1.4. Clinical Trial End-Point Analysis
5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
5.10. 4D Pharma
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Microbiome-based Drug Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Biosortia Pharmaceuticals
5.11.1. Company Overview
5.11.2 Microbiome-based Drug Portfolio
5.11.3. Recent Developments and Future Outlook

5.12. Qu Biologics
5.12.1. Company Overview
5.12.2. Microbiome-based Drug Portfolio
5.12.3. Recent Developments and Future Outlook

5.13. Servatus
5.13.1 Company Overview
5.13.2. Microbiome-based Drug Portfolio
5.13.3. Recent Developments and Future Outlook

6. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
6.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
6.3.1. Analysis by Stage of Development
6.3.2. Analysis by Type of Test
6.3.3. Analysis by Stage of Development and Type of Test
6.3.4. Analysis by Type of Sample Analyzed
6.3.5. Analysis by Type of Screening Technique
6.3.6. Analysis by Target Indication 
6.3.7. Analysis by Therapeutic Area
6.3.8. Analysis by Purpose of Test

6.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size
6.4.3. Analysis by Location of Headquarters
6.4.4. Analysis by Company Size and Location of Headquarters

7. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES
7.1. Chapter Overview
7.2. Shoreline Biome
7.2.1. Company Overview
7.2.2. Microbiome Test Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. DNA Genotek
7.3.1. Company Overview
7.3.2. Microbiome Test Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. Invivo Healthcare
7.4.1. Company Overview
7.4.2. Microbiome Test Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. GoodGut
7.5.1. Company Overview
7.5.2. Microbiome Test Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. BiomeDx
7.6.1. Company Overview
7.6.2. Microbiome Test Portfolio
7.6.3. Recent Developments and Future Outlook

8. FECAL MICROBIOTA THERAPY (FMT)
8.1. Chapter Overview
8.2. Introduction to Fecal Microbiota Therapies (FMT)
8.3. Historical Overview
8.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
8.4.1. Donor Selection
8.4.2. Administration Procedure
8.4.3. Routes of Administration
8.4.4. Consequences and Adverse Events
8.4.5. Clinical Guidelines Associated with FMT

8.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
8.6. Insurance Coverage for Fecal Microbiota Therapies

8.7. Fecal Microbiota Therapies: Marketed and Development Pipeline 
8.7.1. Analysis by Application Area
8.7.2. Analysis by Status of Development
8.7.3. Analysis by Target Indication
8.7.1.2. Analysis by Therapeutic Area
8.7.1.3. Analysis by Route of Administration

8.7.2. Fecal Microbiota Therapies: List of Developers
8.7.2.1. Analysis by Year of Establishment
8.7.2.2. Analysis by Company Size
8.7.2.3. Analysis by Location of Headquarters

9. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Fecal Microbiota Therapies: Clinical Trial Analysis
9.3.1. Analysis by Trial Status
9.3.2. Analysis by Trial Registration Year
9.3.3. Analysis by Trial Recruitment Status
9.3.4. Analysis by Trial Phase and Number of Patients Enrolled
9.3.5. Analysis by Study Design
9.3.6. Leading Industry Players: Analysis by Number of Registered Trials
9.3.7. Leading Non-industry Players: Analysis by Number of Registered Trials
9.3.8. Analysis by Trial Location
9.3.9. Analysis by Trial Status and Geography

10. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
10.1. Chapter Overview
10.2. AC Matrix: An Overview
10.2.1. Strong Business Units
10.2.2. Average Business Units
10.2.3. Weak Business Units

10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Plotting the Information
10.5. AC Matrix: Analyzing the Data
10.5.1. Strong Business Units
10.5.2. Average Business Units
10.5.3. Weak Business Units

10.6. Concluding Remarks

11. START-UP HEALTH INDEXING
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Benchmarking of Start-ups
11.3.1. Analysis by Portfolio Diversity
11.3.2. Analysis by Phase of Development 
11.3.3. Analysis by Diversity in Indication
11.3.4. Analysis by Funding Amount
11.3.5. Analysis by Partnership Activity
11.3.6. Start-up Health Indexing: Roots Analysis Perspective
11.3.7. Start-up Health Indexing: Top Five Start-ups

12. KEY THERAPEUTIC AREAS
12.1. Chapter Overview
12.2. Metabolic Disorders
12.2.1. Diabetes
12.2.1.1. Disease Description
12.2.1.2. Associated Health Risks / Complications
12.2.1.3. Epidemiology
12.2.1.4. Disease Diagnosis
12.2.1.5. Current Treatment Options
12.2.1.5.1. Insulin Therapies
12.2.1.5.2. Non-Insulin Therapies
12.2.1.6. Side Effects of Current Treatment Options
12.2.1.7. Microbiome Therapeutics for Diabetes

12.2.2. Lactose Intolerance
12.2.2.1. Disease Description
12.2.2.2. Epidemiology
12.2.2.3. Current Treatment Options
12.2.2.4. Microbiome Therapeutics for Lactose Intolerance

12.2.3. Nonalcoholic Steatohepatitis (NASH)
12.2.3.1. Disease Description
12.2.3.2. Epidemiology
12.2.3.3. Current Treatment Options
12.2.3.4. Microbiome Therapeutics for NASH

12.2.4. Primary Hyperoxaluria
12.2.4.1. Disease Description
12.2.4.2. Epidemiology
12.2.4.3. Current Treatment Options
12.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria

12.2.5. Obesity
12.2.5.1. Disease Description
12.2.5.2. Epidemiology
12.2.5.3. Current Treatment Options
12.2.5.4. Side Effects of Current Treatment Options
12.2.5.5. Microbiome Therapeutics for Obesity

12.3. Digestive and Gastrointestinal Disorders
12.3.1. Crohn’s Disease
12.3.1.1. Disease Description
12.3.1.2. Epidemiology
12.3.1.3. Current Treatment Options
12.3.1.4. Side Effects of Current Treatment Options
12.3.1.5. Microbiome Therapeutics for Crohn’s Disease
12.3.2. Irritable Bowel Syndrome (IBS)
12.3.2.1. Disease Description
12.3.2.2. Epidemiology
12.3.2.3. Current Treatment Options
12.3.2.4. Microbiome Therapeutics for IBS

12.3.3. Ulcerative Colitis
12.3.3.1. Disease Description
12.3.3.2. Epidemiology
12.3.3.3. Current Treatment Options
12.3.3.4. Side Effects of Current Treatment Options
12.3.3.5. Microbiome Therapeutics for Ulcerative Colitis

12.4. Oncological Indications
12.4.1. Colorectal Cancer
12.4.1.1. Disease Description
12.4.1.2. Epidemiology
12.4.1.3. Current Treatment Options
12.4.1.4. Side Effects of Current Treatments
12.4.1.5. Microbiome Therapeutics for Colorectal Cancer

12.4.2. Lung Cancer
12.4.2.1. Disease Description
12.4.2.2. Epidemiology
12.4.2.3. Current Treatment Options
12.4.2.4. Side Effects of Current Treatment Options
12.4.2.5. Microbiome Therapeutics for Lung Cancer

12.5. Dermatological Disorders
12.5.1. Acne Vulgaris
12.5.1.1. Disease Description
12.5.1.2. Epidemiology
12.5.1.3. Current Treatment Options
12.5.1.4. Side Effects of Current Treatment Options
12.5.1.5. Microbiome Therapeutics for Acne Vulgaris
12.6. Infectious Diseases
12.6.1. Clostridium Difficile Infections (CDIs)
12.6.1.1. Disease Description
12.6.1.2. Epidemiology
12.6.1.3. Disease Diagnosis
12.6.1.4. Current Treatment Options
12.6.1.5. Side Effects of Current Treatment Options
12.6.1.6. Microbiome Therapeutics for CDI

12.6.2. Bacterial Vaginosis
12.6.2.1. Disease Description
12.6.2.2. Epidemiology
12.6.2.3. Current Treatment Options
12.6.2.4. Side Effects of Current Treatment Options
12.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. Human Microbiome: List of Partnerships and Collaborations
13.4. Analysis by Year of Partnership
13.5. Analysis by Type of Partnership
13.6. Analysis by Year and Type of Partnership
13.7. Analysis by Type of Product
13.8. Analysis by Target Indication
13.9. Analysis by Therapeutic Area
13.10. Analysis by Type of Company
13.11. Analysis by Type of Partner
13.12. Most Active Players: Analysis by Number of Partnerships
13.13. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
14.3.1. Analysis by Year of Investment
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Type of Company
14.3.5. Analysis by Purpose of Funding
14.3.6. Analysis by Type of Product
14.3.7. Analysis by Target Indication 
14.3.9. Analysis by Therapeutic Area
14.3.10. Analysis by Geography
14.3.11. Most Active Players: Analysis by Number of Instances
14.3.12. Most Active Players: Analysis by Amount Invested
14.3.12. Most Active Investors: Analysis by Number of Instances
14.3.13 Funding and Investment Summary

15. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS
15.1. Chapter Overview
15.2. Manufacturing Microbiome Therapeutics
15.2.1. Key Steps Involved
15.2.2. Associated Challenges
15.2.3. Growing Demand for Contract Manufacturing Services

15.2.4. Contract Manufacturing Organizations (CMOs)
17.2.4.1. Introduction to Contract Manufacturing
15.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
15.2.5.1. Analysis by Year of Establishment
15.2.5.2. Analysis by Company Size
15.2.5.3. Analysis by Location of Headquarters
15.2.5.4. Analysis by Scale of Operation
15.2.5.5. Analysis by Type of Product Manufactured
15.2.5.6. Analysis by Type of Formulation
15.2.5.7. Analysis by Scale of Operation and Type of Formulation

15.3. Key Considerations for Selecting a CMO / CRO Partner

16. BIG DATA AND MICROBIOME THERAPEUTICS
16.1. Chapter Overview
16.2. Introduction to Big Data
16.3. Internet of Things (IoT)
16.4. Growing Interest in Big Data: Google Trends Analysis
16.5. Key Application Areas

16.6. Big Data in Microbiome Research
16.6.1. Microbiome Data and Personalized Medicine
16.6.2. Microbiome-related Data Management Challenges
16.6.3. National Microbiome Data Center

16.7. Big Data Services for Microbiome Research: List of Companies
16.8. Big Data Services for Microbiome Research: Profiles of Key Players
16.8.1. Human Longevity
16.8.1.1. Company Overview
16.8.1.2. Technology and Service Portfolio
16.8.1.3. Recent Developments and Future Outlook

16.8.2. Resilient Biotics
16.8.2.1. Company Overview
16.8.2.2. Technology and Service Portfolio
16.8.2.3. Recent Developments and Future Outlook

16.8.3. Resphera Biosciences
16.8.3.1. Company Overview
16.8.3.2. Technology and Service Portfolio
16.8.3.3. Recent Developments and Future Outlook

17. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions
17.3. Forecast Methodology

17.4. Global Microbiome Therapeutics Market, 2022-2035
17.4.1. Microbiome Therapeutics Market: Distribution by Type of Product 2022-2035
17.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035
17.4.1.2. Microbiome Therapeutics Market for Other Drugs, 2022-2035

17.4.2. Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022-2035
17.4.2.1. Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035
17.4.2.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035
17.4.2.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035
17.4.2.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035

17.4.3. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022-2035
17.4.3.1. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035
17.4.3.2. Microbiome Therapeutics Market for Infectious Diseases, 2022-2035
17.4.3.3. Microbiome Therapeutics Market for Rare Disorders, 2022-2035

17.4.4. Microbiome Therapeutics Market: Route of Administration, 2022-2035
17.4.4.1. Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035
17.4.4.2. Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035

17.4.5. Microbiome Therapeutics Market: Distribution by Type of Formulation, 2022-2035
17.4.5.1. Microbiome Therapeutics Market for Capsules, 2022-2035
17.4.5.2. Microbiome Therapeutics Market for Suspensions, 2022-2035
17.4.5.3. Microbiome Therapeutics Market for Enemas, 2022-2035

17.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035
17.4.6.1. Microbiome Therapeutics Market in North America, 2022-2035
17.4.6.2. Microbiome Therapeutics Market in Europe, 2022-2035
17.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035

17.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035

17.4.8. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035
17.4.8.1. SER-109 (Seres Therapeutics)
17.4.8.2. RBX2660 (ReBiotix)
17.4.8.3. CP101 (Finch Therapeutics)
17.4.8.4. IBP-9414 (Infant bacterial Therapeutics)
17.4.8.5. Oxabact (OxThera)
17.4.8.6. MaaT013 (MaaT Pharma)

18. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3 Forecast Methodology
18.4. Global Human Microbiome Diagnostic Test Market, 2022-2035
18.4.1. Human Microbiome Diagnostic Tests Market by Target Indication, 2022 and 2035
18.4.1.1. Human Microbiome Diagnostic Tests Market for Inflammatory Bowel Syndrome, 2022-2035
18.4.1.2. Human Microbiome Diagnostic Tests Market for Irritable Bowel Disease, 2022-2035
18.4.1.3. Human Microbiome Diagnostic Tests Market for Colorectal Cancer, 2022-2035
18.4.1.3. Human Microbiome Diagnostic Tests Market for Diabetes Mellitus, 2022-2035

18.4.2. Human Microbiome Diagnostic Tests Market: Distribution by Therapeutic Area, 2022 and 2035
18.4.2.1. Human Microbiome Diagnostic Tests Market for Digestive and Gastrointestinal Disorders, 2022-2035
18.4.2.2. Human Microbiome Diagnostic Tests Market for Oncological Disorders, 2022-2035
18.4.2.3. Human Microbiome Diagnostic Tests Market for Metabolic Disorders, 2022-2035

18.4.3. Human Microbiome Diagnostic Tests Market: Distribution by Key Geographical Regions, 2022 and 2035
18.4.3.1. Human Microbiome Diagnostic Tests Market in North America, 2022-2035
18.4.3.2. Human Microbiome Diagnostic Tests Market in Europe, 2022-2035
18.4.3.3. Human Microbiome Diagnostic Tests Market in Asia Pacific, 2022-2035

19. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Forecast Methodology and Key Assumptions
19.3. Global Fecal Microbiota Therapies Market, 2022-2035
19.3.1. Global Fecal Microbiota Therapies Market, 2022-2035 (By Value)
19.3.2. Global Fecal Microbiota Therapies Market, 2022-2035 (By Value)
19.4.2. Overall FMT Market, 2022-2035 (By Volume)

19.5. Overall Microbiome Market by Product Offerings, 2022-2035

20. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES
20.1. Chapter Overview
20.2. List of Microbiome Products in Non-Pharmaceutical Industry
20.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
20.3. Applications of Microbiome Based Products in Agriculture Industry
20.4. Future Perspectives

21. CONCLUDING REMARKS

22. EXECUTIVE INSIGHTS
22.1 Chapter Overview
22.2 4D Pharma
22.2.1. Company / Organization Snapshot
22.2.2. Interview Transcript: Charlie Badham, Senior Manager, Corporate Development

22.3. Quorum Innovations
22. 3.1. Company / Organization Snapshot
22.3.2. Interview Transcript: Nicholas Monsul, Co-founder and Chairman

22.4. Floragraph
22.4.1. Company / Organization Snapshot
22.4.3. Interview Transcript: Alicia Scheffer, Chief Executive Officer

22.5. Pacific Northwest National Laboratories
22.5.1. Company / Organization Snapshot
22.5.2. Interview Transcript: Aaron Wright, Senior Scientist

22.6. Chung Mei Pharmaceutical
22.6.1. Company / Organization Snapshot
22.6.2. Interview Transcript: Alexander Lin, Associate General Manager

22.7. Universal Stabilization Technologies
22.7.1. Company / Organization Snapshot
22.7.2. Interview Transcript: Alexander Segal, Ex-Vice President, Business Development

22.8. BiomX
22.8.1. Company / Organization Snapshot
22.8.2. Interview Transcript: Assaf Oron, Chief Business Officer

22.9. List Biological Laboratories
22.9.1. Company / Organization Snapshot
22.9.2. Interview Transcript: Debbie Pinkston, Ex-Vice President, Sales and Business Development

22.10. S-Biomedic
22.10.1. Company / Organization Snapshot
22.10.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

22.11. Pendulum Therapeutics (formerly known as Whole Biome)
22.11.1. Company / Organization Snapshot
22.11.2. Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer

22.12. Siolta Therapeutics
22.12.1 Company / Organization Snapshot
22.12.2. Interview Transcripts: Nikole Kimes, Co-founder and Chief Executive Officer

22.13. OpenBiome
22.13.1. Company / Organization Snapshot
22.13.2. Interview Transcripts: James Burges, Ex-Co-founder and Vice President of Innovation

22.14. Metabiomics
22.14.1. Company / Organization Snapshot
22.14.2. Interview Transcript: Gregory J Kuehn, Vice President, Business Development and Marketing

22.15. Assembly Biosciences
22.15.1. Company / Organization Snapshot
22.15.2. Interview Transcript: JP Benya, Ex-Vice President, Operations

22.16. Rebiotix
22.16.1. Company / Organization Snapshot
22.16.2. Interview Transcript: Lee Jones, President and Chief Executive Officer

22.17. MicroBiome Therapeutics
22.17.1. Company / Organization Snapshot
22.17.2. Interview Transcript: Mark Heiman, Ex-Chief Scientific Officer and Vice President

22.18. Da Volterra
22.18.1. Company / Organization Snapshot
22.18.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Strategy Officer

23. APPENDIX I: TABULATED DATA

24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Human Microbiome Therapeutics
Figure 2.2 Executive Summary: Overall Market Landscape of Human Microbiome Diagnostics and Screening / Profiling Tests
Figure 2.3 Executive Summary: Overall Market Landscape of Fecal Microbiota Therapies and Clinical Trial Analysis
Figure 2.4 Executive Summary: Partnerships and Collaborations
Figure 2.5 Executive Summary: Funding and Investment Analysis
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis for Microbiome Therapeutics
Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis for Microbiome Diagnostics and Fecal Microbiota Therapies
Figure 3.1 Benefits of the Human Microbiota
Figure 3.2 Factors Affecting Gut Microbiota
Figure 3.3 Factors Affecting Gut Microbiota in Infants
Figure 3.4 Impact of Diet on Gut Microbiota
Figure 3.5 Types of Microbiome-Based Therapeutics
Figure 3.6 Approaches to Design Microbiome Therapeutics
Figure 3.7 Health Benefits of Probiotics
Figure 3.8 Mechanism of Action of Probiotics
Figure 3.9 Beneficial Bacterial Strains for Probiotics
Figure 3.10 Key Achievements of the Human Microbiome Project (HMP)
Figure 3.11 Challenges Associated with the Development of Microbiome Therapeutics
Figure 4.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Figure 4.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Figure 4.3. Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Figure 4.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Figure 4.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
Figure 4.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
Figure 4.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Figure 4.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
Figure 4.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
Figure 4.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
Figure 4.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Figure 4.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Figure 4.15. Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Figure 4.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Figure 4.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
Figure 4.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
Figure 4.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 4.20 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Figure 4.21 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Figure 4.22 Microbiome Therapeutic Developers: Distribution by Company Size
Figure 4.23 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.24 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 5.1 Rebiotix: Financial Information, 2017-2021 (USD Million)
Figure 5.2 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
Figure 5.3 4D Pharma: Financial Information, 2017-2021 (USD Million)
Figure 6.1 Key Steps in 16S rRNA Gene Sequence Analysis
Figure 6.2 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Figure 6.3 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
Figure 6.4 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
Figure 6.5 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Figure 6.6 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Figure 6.7 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Figure 6.8 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Figure 6.9 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Figure 6.10 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
Figure 6.11 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
Figure 6.12 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
Figure 6.13 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
Figure 8.1 Working Mechanism of a Microflora Refinement System
Figure 8.2 Fecal Microbiota Therapies: Distribution by Application Area
Figure 8.3 Fecal Microbiota Therapies: Distribution by Status of Development
Figure 8.4 Fecal Microbiota Therapies: Distribution by Target Indication
Figure 8.5 Fecal Microbiota Therapies: Distribution by Therapeutic Area
Figure 8.6 Fecal Microbiota Therapies: Distribution by Route of Administration
Figure 8.7 Fecal Microbiota Therapies Developers: Distribution by Year of Establishment
Figure 8.8 Fecal Microbiota Therapies Developers: Distribution by Company Size
Figure 8.9 Fecal Microbiota Therapies Developers: Distribution by Location of Headquarters
Figure 9.1 Clinical Trial Analysis: Scope and Methodology
Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2015 – 2022 (till April)
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre 2015 – 2022 (till April)
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Figure 9.7 Clinical Trial Analysis: Distribution by Study Design
Figure 9.8 Leading Industry Players: Distribution by Number of Registered Trials
Figure 9.9 Leading Non-industry Players: Distribution by Number of Registered Trials\
Figure 9.10 Clinical Trial Analysis: Analysis by Trial Location
Figure 9.11 Clinical Trial Analysis: Analysis by Trial Status and Geography
Figure 10.1 AC Matrix: Pictorial Representation
Figure 10.2 AC Matrix: Positioning of Different Indications
Figure 11.1 Benchmarking of Start-ups: Distribution by Portfolio Diversity
Figure 11.2 Benchmarking of Start-ups: Distribution by Phase of Development
Figure 11.3 Benchmarking of Start-ups: Distribution by Indication Diversity
Figure 11.4 Benchmarking of Start-ups: Distribution by Funding Amount
Figure 11.5 Benchmarking of Start-ups: Distribution by Partnership Activity
Figure 11.6 Start-up Health Indexing: Roots Analysis Perspective
Figure 11.7 Start-up Heal Indexing: Leading Companies
Figure 12.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 12.2 Non-Insulin Therapies for Diabetes
Figure 12.3 Weight Categories as per BMI Calculations
Figure 12.4 Causes of Obesity in Children
Figure 12.5 Obese Population: Distribution by Key Regions
Figure 13.1 Partnerships and Collaborations: Distribution of Cumulative Year-wise Trend, 2017-2022 (till March)
Figure 13.2 Partnerships and Collaborations: Distribution of Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution of Year and Type of Partnership, 2017-2022 (till March)
Figure 13.4 Partnerships and Collaborations: Distribution of Type of Collaborator
Figure 13.5 Partnerships and Collaborations: Distribution of Target Indication
Figure 13.6 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication
Figure 13.7 Partnerships and Collaborations: Distribution of Therapeutic Area
Figure 13.8 Most Active Players: Distribution by Number of Partnerships
Figure 13.9 Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
Figure 13.10 Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
Figure 13.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 14.1 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million), 2017-2022 (till March)
Figure 14.2 Funding and Investment Analysis: Distribution by Year of Establishment and Type of Funding, 2017-2022 (till March)
Figure 14.3 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2017-2022 (till March)
Figure 14.4 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2017-2022 (till March)
Figure 14.5 Funding and Investment Analysis: Distribution by Type of Funding
Figure 14.6 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 14.7 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 14.8 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 14.9 Funding and Investment Analysis: Distribution by Type of Product
Figure 14.10 Funding and Investment Analysis: Distribution by Target Indication
Figure 14.11 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 14.12 Funding and Investment Analysis: Distribution by Type of Product, Type of Funding and Amount Invested (USD Million)
Figure 14.13 Funding and Investment Analysis: Distribution by Region
Figure 14.14 Most Active Players: Distribution by Number of Instances
Figure 14.15 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 14.16 Key Investors: Distribution by Number of Funding Instances
Figure 14.17 Funding and Investment Summary, 2017-2022 (USD Million)
Figure 15.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Figure 15.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Figure 15.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Figure 15.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Figure 15.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 15.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Figure 15.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Figure 16.1 Big Data: The Three V’s
Figure 16.2 Internet of Things: Framework
Figure 16.3 Internet of Things: Applications in Healthcare
Figure 16.4 Big Data: Google Trends Analysis
Figure 16.4 Big Data and Microbiome: Google Trends
Figure 16.5 Big Data: Key Application Areas
Figure 16.6 Big Data: Opportunities in Healthcare
Figure 16.7 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
Figure 16.8 Challenges Associated with Microbiome-related Big Data Management
Figure 17.1 Global Human Microbiome Therapeutics Market, 2022-2035 (USD Billion)
Figure 17.2 Human Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035 (USD Million)
Figure 17.3 Human Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
Figure 17.4 Human Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
Figure 17.5 Human Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
Figure 17.6 Human Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
Figure 17.7 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
Figure 17.8 Human Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
Figure 17.9 Human Microbiome Therapeutics Market for Graft versus Host Disease, 2022-2035 (USD Million)
Figure 17.10 Human Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035 (USD Million)
Figure 17.11 Human Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 17.12 Human Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Figure 17.13 Human Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
Figure 17.14 Human Microbiome Therapeutics Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Figure 17.15 Human Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
Figure 17.16 Human Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
Figure 17.17 Human Microbiome Therapeutics Market: Distribution by Type of Formulation, 2023 and 2035 (USD Million)
Figure 17.18 Human Microbiome Therapeutics Market for Capsules, 2022-2035 (USD Million)
Figure 17.19 Human Microbiome Therapeutics Market for Suspensions, 2022-2035 (USD Million)
Figure 17.20 Human Microbiome Therapeutics Market for Enemas, 2022-2035 (USD Million)
Figure 17.21 Human Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 17.22 Human Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
Figure 17.23 Human Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
Figure 17.24 Human Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 17.25 Human Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
Figure 17.26 Sales Forecast: SER-109, 2023-2035 (USD Million)
Figure 17.27 Sales Forecast: RBX2660, 2024-2035 (USD Million)
Figure 17.28 Sales Forecast: CP101, 2025-2035 (USD Million)
Figure 17.29 Sales Forecast: IBP-9414, 2025-2035 (USD Million)
Figure 17.30 Sales Forecast: Oxabact, 2023-2035 (USD Million)
Figure 17.31 Sales Forecast: MaaT013, 2025-2035 (USD Million)
Figure 18.1 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
Figure 18.2 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
Figure 18.3 Microbiome Diagnostics Market for Irritable Bowel Syndrome, 2022-2035 (USD Million)
Figure 18.4 Microbiome Diagnostics Market for Inflammatory Bowel Disease, 2022-2035 (USD Million)
Figure 18.5 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
Figure 18.6 Microbiome Diagnostics Market for Diabetes Mellitus, 2022-2035 (USD Million)
Figure 18.7 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
Figure 18.8 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Figure 18.9 Microbiome Diagnostics Market for Oncological Disorders, 2022-2035 (USD Million)
Figure 18.10 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 18.11 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 18.12 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
Figure 18.13 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
Figure 18.14 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 19.1 Global Fecal Microbiota Therapies Market, 2022-2035 (USD Million)
Figure 19.2 Global Microbiota Therapies Market, 2022-2035 (Million Procedures)
Figure 19.3 Fecal Microbiota Therapies Market in North America, 2022-2035 (USD Million)
Figure 19.4 Fecal Microbiota Therapies Market in Europe, 2022-2035 (USD Million)
Figure 19.5 Fecal Microbiota Therapies Market in Asia Pacific, 2022-2035 (USD Million)
Figure 19.6 Fecal Microbiota Therapies Market in North America, 2022-2035 (Million Procedures)
Figure 19.7 Fecal Microbiota Therapies in Europe, 2022-2035 (Million Procedures)
Figure 19.8 Fecal Microbiota Therapies Market in Asia Pacific, 2022-2035 (Million Procedures)
Figure 19.9 Overall Human Microbiome Market: Distribution by Product Offerings, 2022 and 2035 (USD Million)
Figure 21.1 Concluding Remarks: Human Microbiome Therapeutics Landscape
Figure 21.2 Concluding Remarks: Human Microbiome Therapeutics Landscape
Figure 21.3 Concluding Remarks: Human Microbiome Diagnostics Landscape
Figure 21.4 Concluding Remarks: Fecal Microbiota Therapies Landscape
Figure 21.5 Concluding Remarks: Funding and Investment Analysis
Figure 21.6 Concluding Remarks: Partnerships and Collaborations
Figure 21.7 Concluding Remarks: Start-up Health Indexing
Figure 21.8 Concluding Remarks: Human Microbiome Market Sizing and Opportunity Analysis
Figure 21.9 Concluding Remarks: Microbiome Therapeutics Market Sizing and Opportunity Analysis
Figure 21.10 Concluding Remarks: Microbiome Diagnostic Tests Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Types of Microbiota in the Gastrointestinal Tract
Table 3.2 Common Instances of Misuse of Antibiotics
Table 3.3 Impact of Antibiotics on Intestinal Microflora
Table 3.4 List of Microorganisms Classified as Class I Carcinogens by the IARC
Table 3.5 Relationship Between Microbiome and Disease Progression
Table 3.6 Impact of Drug-Microbiome Interactions
Table 3.7 List of Foods Containing Prebiotics
Table 4.1 Microbiome Therapeutics: Clinical Pipeline
Table 4.2 Clinical Phase Microbiome Therapeutics: Information on Type of Molecule and Route of Administration
Table 4.3 Clinical Phase Microbiome Therapeutics: Additional Information
Table 4.4 Microbiome Therapeutics: Preclinical Pipeline
Table 4.5 Preclinical Phase Microbiome Therapeutics: Additional Information
Table 4.6 Microbiome Therapeutics: List of Drug Developers
Table 5.1 Microbiome Therapeutic Developers: Companies with Candidates in Highest Phase of Development
Table 5.2 Finch Therapeutics: Microbiome-Based Product Portfolio
Table 5.3 CP101: Current Status of Development
Table 5.4 CP101: Clinical Studies
Table 5.5 Finch Therapeutics: Recent Developments and Future Outlook
Table 5.6 Infant Bacterial Therapeutics: Microbiome-Based Product Portfolio
Table 5.7 IBP-9414: Current Status of Development
Table 5.8 IBP-9414: Clinical Studies
Table 5.9 Infant Bacterial Therapeutics: Recent Developments and Future Outlook
Table 5.10 MaaT Pharma: Microbiome-Based Product Portfolio
Table 5.11 MaaT013: Current Status of Development
Table 5.12 MaaT013: Clinical Studies
Table 5.13 MaaT Pharma: Recent Developments and Future Outlook
Table 5.14 OxThera: Microbiome-Based Product Portfolio
Table 5.15 Oxabact: Current Status of Development
Table 5.16 Oxabact: Clinical Studies
Table 5.17 OxThera: Recent Developments and Future Outlook
Table 5.18 Rebiotix: Microbiome-Based Product Portfolio
Table 5.19 RBX2660: Current Status of Development
Table 5.20 RBX2660: Clinical Studies
Table 5.21 Rebiotix: Recent Developments and Future Outlook
Table 5.22 Seres Therapeutics: Microbiome-Based Product Portfolio
Table 5.23 SER-109: Current Status of Development
Table 5.24 SER-109: Clinical Studies
Table 5.25 Seres Therapeutics: Recent Developments and Future Outlook
Table 5.26 Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
Table 5.27 4D Pharma: Financial Information
Table 5.28 4D Pharma: Recent Developments and Future Outlook
Table 5.29 Biosortia Pharmaceuticals: Recent Developments and Future Outlook
Table 5.30 Qu Biologics: Recent Developments and Future Outlook
Table 5.31 Servatus: Recent Developments and Future Outlook
Table 6.1 Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Development Pipeline
Table 6.2 Microbiome Diagnostics and Screening / Profiling Tests: List of Developers
Table 7.1 Shoreline Biome: Company Overview
Table 7.2 Shoreline Biome: Microbiome Test Portfolio
Table 7.3 Shoreline Biome: Recent Developments and Future Outlook
Table 7.4 DNA Genotek: Company Overview
Table 7.5 DNA Genotek: Microbiome Test Portfolio
Table 7.6 DNA Genotek: Recent Developments and Future Outlook
Table 7.7 Invivo Healthcare: Company Overview
Table 7.8 Invivo Healthcare: Microbiome Test Portfolio
Table 7.9 Invivo Healthcare: Recent Developments and Future Outlook
Table 7.10 GoodGut: Company Overview
Table 7.11 GoodGut: Microbiome Test Portfolio
Table 7.12 GoodGut: Recent Developments and Future Outlook
Table 7.13 BiomeDx: Company Overview
Table 7.14 BiomeDx: Microbiome Test Portfolio
Table 7.15 BiomeDx: Recent Developments and Future Outlook
Table 8.1 Comparison between Various Routes of Administration of FMT
Table 8.2 FMT: Summary of Clinical Guidelines
Table 8.3 FMT: Summary of Insurance Coverage Payer
Table 8.4 FMT: Marketed and Development Pipeline
Table 8.5 FMT: List of Developers
Table 8.6 List of Stool Banks for FMT Development
Table 8.7 Fecal Microbiota Transplant and Human Microbiome Transplant (HMT): Key Differences in Processing
Table 8.8 Flora Medicine: Fecal Microbiota Transplant Treatment Cost
Table 8.9 OpenBiome: Types of FMT Formulations
Table 9.1 Fecal Microbiota Transplant: List of Registered Clinical Trials
Table 12.1 Diabetes: Current Treatment Options
Table 12.2 Diabetes: Side Effects of Current Treatment Options
Table 12.3 Microbiome Therapeutics Candidates for Diabetes
Table 12.4 Microbiome Therapeutics Candidates for Lactose Intolerance
Table 12.5 Microbiome Therapeutics Candidates for NASH
Table 12.6 Microbiome Therapeutics Candidates for Primary Hyperoxaluria
Table 12.7 Obesity: Side Effects of Current Treatment Options
Table 12.8 Microbiome Therapeutic Candidates for Obesity
Table 12.9 Crohn’s Disease: Current Treatment Options
Table 12.10 Crohn’s Disease: Side Effects of Current Treatment Options
Table 12.11 Microbiome Therapeutics Candidates for Crohn’s Disease
Table 12.12 IBS: Current Treatment Options
Table 12.13 Microbiome Therapeutics Candidates for IBS
Table 12.14 Ulcerative Colitis: Current Treatment Options
Table 12.15 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 12.16 Microbiome Therapeutics Candidates for Ulcerative Colitis
Table 12.17 Colorectal Cancer: Side Effects of Current Treatment Options
Table 12.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
Table 12.19 Lung Cancer: Current Treatment Options
Table 12.20 Lung Cancer: Side Effects of Current Treatment Options
Table 12.21 Microbiome Therapeutics Candidates for Lung Cancer
Table 12.22 Acne Vulgaris: Current Treatment Options
Table 12.23 Acne Vulgaris: Side Effects of Current Treatment Options
Table 12.24 Microbiome Therapeutics Candidates for Acne Vulgaris
Table 12.25 CDI: Diagnostic Testing
Table 12.26 CDI: Severity Scoring System and Treatment Options
Table 12.27 CDI: Side Effects of Current Treatment Options
Table 12.28 Microbiome Therapeutics Candidates for CDI
Table 12.29 Bacterial Vaginosis: Current Treatment Options
Table 12.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
Table 12.31 Microbiome Therapeutics Candidates for Bacterial Vaginosis
Table 13.1 Human Microbiome: List of Partnerships and Collaborations, 2017-2022 (till March)
Table 14.1 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, 2017-2022 (till March)
Table 14.2 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, 2017-2022 (till March)
Table 14.3 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Location of Headquarters, 2017-2022 (till March)
Table 15.1 Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size, Accreditation Received and Scale of Operation
Table 15.2 Microbiome Contract Manufacturers: Information on Type of Product Manufactured
Table 15.3 Microbiome Contract Manufacturers: Information on Type of Formulation
Table 15.4 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
Table 16.1 List of Companies Using Big Data for Microbiome Research
Table 16.2 Human Longevity: Partnerships and Collaborations
Table 16.3 Human Longevity: Venture Capital Funding
Table 16.4 Resilient Biotics: Venture Capital Funding
Table 20.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
Table 20.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
Table 22.1 Quorum Innovations: Company / Organization Snapshot
Table 22.2 Floragraph: Company / Organization Snapshot
Table 22.3 Pacific Northwest National Laboratories: Company / Organization Snapshot
Table 22.4 Chung Mei Pharmaceutical: Company / Organization Snapshot
Table 22.5 Universal Stabilization technologies: Company / Organization Snapshot
Table 22.6 BiomX: Company / Organization Snapshot
Table 22.7 List Biological Laboratories: Company / Organization Snapshot
Table 22.8 S-Biomedic: Company / Organization Snapshot
Table 22.9 Pendulum Therapeutics: Company / Organization Snapshot
Table 22.10 Siolta Therapeutics: Company / Organization Snapshot
Table 22.11 OpenBiome: Company / Organization Snapshot
Table 22.12 Metabiomics: Company / Organization Snapshot
Table 22.13 Assembly Biosciences: Company / Organization Snapshot
Table 22.14 Microbiome Therapeutics: Company / Organization Snapshot
Table 22.15 Da Volterra: Company Snapshot
Table 23.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Table 23.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Table 23.3 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 23.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Table 23.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
Table 23.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
Table 23.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Table 23.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Table 23.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
Table 23.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
Table 23.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
Table 23.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
Table 23.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Table 23.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Table 23.15 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 23.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Table 23.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
Table 23.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
Table 23.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Table 23.20 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Table 23.21 Microbiome Therapeutic Developers: Distribution by Company Size
Table 23.22 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Table 23.23 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
Table 23.24 4D Pharma: Financial Information, 2017-2021 (USD Million)
Table 23.25 Ferring Pharmaceuticals: Financial Information, 2019-2021 (USD Million)
Table 23.26 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Table 23.27 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
Table 23.28 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
Table 23.29 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Table 23.30 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Table 23.31 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Table 23.32 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Table 23.33 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Table 23.34 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
Table 23.35 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
Table 23.36 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
Table 23.37 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
Table 23.38 Fecal Microbiota Transplantation: Distribution by Application Area
Table 23.39 Fecal Microbiota Transplantation: Distribution by Status of Development
Table 23.40 Fecal Microbiota Transplantation: Distribution by Target Indication
Table 23.41 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
Table 23.42 Fecal Microbiota Transplantation: Distribution by Route of Administration
Table 23.43 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
Table 23.44 Fecal Microbiota Transplantation Developers: Distribution by Company Size
Table 23.45 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
Table 23.46 Clinical Trial Analysis: Distribution by Trial Status
Table 23.47 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2015 – 2022 (till April)
Table 23.48 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre 2015 – 2022 (till April)
Table 23.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 23.50 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 23.51 Clinical Trial Analysis: Distribution by Study Design
Table 23.52 Leading Industry Players: Distribution by Number of Registered Trials
Table 23.53 Leading Non-industry Players: Distribution by Number of Registered Trials\
Table 23.54 Clinical Trial Analysis: Analysis by Trial Location
Table 23.55 Clinical Trial Analysis: Analysis by Trial Status and Geography
Table 23.56 Benchmarking of Start-ups: Distribution by Portfolio Diversity
Table 23.57 Benchmarking of Start-ups: Distribution by Phase of Development
Table 23.58 Benchmarking of Start-ups: Distribution by Indication Diversity
Table 23.59 Benchmarking of Start-ups: Distribution by Funding Amount
Table 23.60 Benchmarking of Start-ups: Distribution by Partnership Activity
Table 23.61 Partnerships and Collaborations: Distribution of Cumulative Year-wise Trend, 2017-2022 (till March)
Table 23.62 Partnerships and Collaborations: Distribution of Type of Partnership
Table 23.63 Partnerships and Collaborations: Distribution of Year and Type of Partnership, 2017-2022 (till March)
Table 23.64 Partnerships and Collaborations: Distribution of Type of Collaborator
Table 23.65 Partnerships and Collaborations: Distribution of Target Indication
Table 23.66 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication
Table 23.67 Partnerships and Collaborations: Distribution of Therapeutic Area
Table 23.68 Most Active Players: Distribution by Number of Partnerships
Table 23.69 Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
Table 23.70 Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
Table 23.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 23.72 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2017-2022 (till March)
Table 23.73 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2017-2022 (till March)
Table 23.74 Funding and Investment Analysis: Distribution by Type of Funding
Table 23.75 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 23.76 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Table 23.77 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 23.78 Funding and Investment Analysis: Distribution by Type of Product
Table 23.79 Funding and Investment Analysis: Distribution by Target Indication
Table 23.80 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 23.81 Funding and Investment Analysis: Distribution by Type of Product, Type of Funding and Amount Invested (USD Million)
Table 23.82 Funding and Investment Analysis: Distribution by Region
Table 23.83 Most Active Players: Distribution by Number of Instances
Table 23.84 Most Active Players: Distribution by Amount Raised (USD Million)
Table 23.85 Key Investors: Distribution by Number of Funding Instances
Table 23.86 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Table 23.87 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Table 23.88 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Table 23.89 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Table 23.90 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Table 23.91 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Table 23.92 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Table 23.93 Global Human Microbiome Therapeutics Market, 2022-2035 (USD Billion)
Table 23.94 Human Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035 (USD Million)
Table 23.95 Human Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
Table 23.96 Human Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
Table 23.97 Human Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
Table 23.98 Human Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
Table 23.99 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
Table 23.100 Human Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
Table 23.101 Human Microbiome Therapeutics Market for Graft versus Host Disease, 2022-2035 (USD Million)
Table 23.102 Human Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035 (USD Million)
Table 23.103 Human Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
Table 23.104 Human Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Table 23.105 Human Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
Table 23.106 Human Microbiome Therapeutics Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Table 23.107 Human Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
Table 23.108 Human Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
Table 23.109 Human Microbiome Therapeutics Market: Distribution by Type of Formulation, 2023 and 2035 (USD Million)
Table 23.110 Human Microbiome Therapeutics Market for Capsules, 2022-2035 (USD Million)
Table 23.111 Human Microbiome Therapeutics Market for Suspensions, 2022-2035 (USD Million)
Table 23.112 Human Microbiome Therapeutics Market for Enemas, 2022-2035 (USD Million)
Table 23.113 Human Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 23.114 Human Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
Table 23.115 Human Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
Table 23.116 Human Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 23.117 Human Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
Table 23.118 Sales Forecast: SER-109, 2023-2035 (USD Million)
Table 23.119 Sales Forecast: RBX2660, 2024-2035 (USD Million)
Table 23.120 Sales Forecast: CP101, 2025-2035 (USD Million)
Table 23.121 Sales Forecast: IBP-9414, 2025-2035 (USD Million)
Table 23.122 Sales Forecast: Oxabact, 2023-2035 (USD Million)
Table 23.123 Sales Forecast: MaaT013, 2025-2035 (USD Million)
Table 23.124 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
Table 23.125 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
Table 23.126 Microbiome Diagnostics Market for Irritable Bowel Syndrome, 2022-2035 (USD Million)
Table 23.127 Microbiome Diagnostics Market for Inflammatory Bowel Disease, 2022-2035 (USD Million)
Table 23.128 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
Table 23.129 Microbiome Diagnostics Market for Diabetes Mellitus, 2022-2035 (USD Million)
Table 23.130 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
Table 23.131 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Table 23.132 Microbiome Diagnostics Market for Oncological Disorders, 2022-2035 (USD Million)
Table 23.133 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
Table 23.134 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 23.135 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
Table 23.136 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
Table 23.137 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 23.138 Global Fecal Microbiota Therapies Market, 2022-2035 (USD Million)
Table 23.139 Global Microbiota Therapies Market, 2022-2035 (Million Procedures)
Table 23.140 Fecal Microbiota Therapies Market in North America, 2022-2035 (USD Million)
Table 23.141 Fecal Microbiota Therapies Market in Europe, 2022-2035 (USD Million)
Table 23.142 Fecal Microbiota Therapies Market in Asia Pacific, 2022-2035 (USD Million)
Table 23.143 Fecal Microbiota Therapies Market in North America, 2022-2035 (Million Procedures)
Table 23.144 Fecal Microbiota Therapies in Europe, 2022-2035 (Million Procedures)
Table 23.145 Fecal Microbiota Therapies Market in Asia Pacific, 2022-2035 (Million Procedures)
Table 23.146 Overall Human Microbiome Market: Distribution by Product Offerings, 2022 and 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report

1. 4D Pharma
2. 8VC
3. Aarhus University
4. Abdul Latif Jameel Health
5. Abstract Ventures
6. Acequia Capital
7. Adapsyn Bioscience
8. Adare Pharmaceuticals (acquired by THL and Frazier)
9. ADM Biopolis
10. AgroParisTech
11. Alexandria Venture Investments
12. Alveolus Bio (subsidiary of ResBiotic)
13. American Gastroenterological Association (AGA)
14. Anatara Life Sciences
15. AOBiome Therapeutics
16. Applied Biosystems
17. Ardigen
18. Arena Pharmaceuticals
19. Armata Pharmaceuticals
20. Arranta Bio
21. ARTIS Ventures
22. ARTPred
23. Asia Microbiota Bank
24. AstraZeneca
25. Atlas Biomed
26. Atmo Biosciences
27. Auggi (acquired by Seed Health)
28. Aumgene Biosciences
29. Auriga Partners
30. Austrian Research Promotion Agency (FFG)
31. Autism Impact Fund
32. Axial Biotherapeutics
33. Azenta Life Sciences
34. Azitra
35. Bacthera
36. Bayer
37. BBG Ventures
38. BD (Becton, Dickinson and Company)
39. Beiersdorf
40. Ben Franklin Technology Partners
41. Bill & Melinda Gates Foundation
42. BIOASTER
43. BioCat
44. Biocodex
45. BioCrossroads
46. BioGaia
47. Biohit
48. Biomathematica 
49. Bio-Me
50. BiomeBank
51. Biomecite Diagnostics
52. Biomedical Advanced Research and Development Authority (BARDA)
53. BioMeD X
54. Biomica
55. Biomics
56. BiomX
57. Bios Partners
58. Biose
59. Biosortia Pharmaceuticals
60. BJP Laboratories
61. Blue Turtle Bio
62. Boehringer Ingelheim
63. Boston Children's Hospital
64. BoxGroup
65. Bpifrance
66. Bristol Myers Squibb
67. British Patient Capital
68. C.R. Bard (acquired by BD (Becton, Dickinson and Company))
69. C3J Therapeutics
70. Caelus Health
71. Cambridge Innovation Capital
72. Cambridge University Hospitals NHS Foundation Trust
73. Cancer Research UK
74. Candela Paramount
75. Cap Innov’Est
76. Capsugel (acquired by Lonza)
77. Carbiotix
78. cerascreen
79. Cerbios-Pharma
80. CHAIN Biotech
81. Chromaderm (acquired by DermBiont)
82. ChunLab
83. City of Hope
84. Civet BioSciences
85. Civilization Ventures
86. CJ Group
87. ClostraBio
88. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
89. Congruent Ventures 
90. Connecticut Innovations
91. COPD Foundation
92. CoreBiome
93. Cornell University
94. Corundum Systems Biology
95. CosmosID
96. Crédit Mutuel Innovation
97. Crestovo
98. Crown Laboratories
99. Cykinso
100. Cytognos
101. Da Volterra
102. Dana-Farber Cancer Institute
103. Danone Manifesto Ventures
104. Darling Ventures
105. Debiopharm
106. DeepBiome Therapeutics
107. Department of Defense (DoD)
108. DermBiont
109. Diagnostic Solutions
110. Diversigen
111. DNA Genotek
112. DoctorsForMe (acquired by Human Longevity)
113. Domain Associates
114. DSM Venturing
115. Eagle Biosciences 
116. Edico Genome (acquired by Illumina)
117. EirGenix
118. Elevate Ventures
119. Emerging Technologies Partners
120. Endoscopy Center of Red Bank
121. Enterin
122. Enterome
123. Equipo Ventures
124. Eurofins ADME BIOANALYSES
125. European Innovation Council (EIC)
126. European Union
127. Evelo Biosciences
128. Evologic Technologies
129. Evvy
130. Exeliom Biosciences
131. Ferring Pharmaceuticals
132. Filgen
133. Finch Therapeutics
134. Flora Medicine
135. Floragraph
136. Fonterra
137. Founders Fund
138. FUJIFILM Diosynth Biotechnologies
139. G9 Ventures
140. Galmed Pharmaceuticals
141. Genentech
142. General Catalyst
143. Genetic Analysis
144. Genetimes Technology
145. GENEWIZ
146. Genome & Company
147. Genopole
148. Genorama
149. Genosys
150. Genova Diagnostics
151. Gilead Sciences
152. Ginkgo Bioworks
153. GISEV
154. Global Brain
155. Goodgut
156. Groken Bioscience
157. GlaxoSmithKline
158. Gustave Roussy
159. Gusto Global
160. Hadasit Medical Research Services and Development 
161. Harvard T.H. Chan School of Public Health
162. Harvard University
163. Heidelberg University
164. Hemi Ventures
165. Hercules Capital
166. Heritage Medical Systems
167. HIPRA
168. Holobiome
169. Hudson Institute of Medical Research
170. Human Longevity
171. Human Ventures
172. iCarbonX
173. Igen Biolab Group
174. Illumina
175. ImmuneBiotech
176. Immuron
177. inBiome
178. Indie Asset Partners
179. Infant Bacterial Therapeutics
180. Innovate UK
181. Inpac Probiotics 
182. INRAE
183. Integrated BioBank of Luxembourg (IBBL)
184. Integrated Sciences
185. Invivo Healthcare
186. IP Group
187. Ixcela
188. Janssen
189. Jeneil Biotech
190. John Theurer Cancer Center
191. Johnson & Johnson
192. Joyance Partners
193. JSR 
194. Juno Bio
195. K3 Ventures
196. Kairos Ventures
197. Kaleido Biosciences
198. Karolinska Institutet
199. KdT Ventures
200. Keiretsu Capital 
201. Khosla Ventures
202. Leadiant Biosciences
203. Leiden University Medical Center
204. Leucine Rich Bio
205. Life Genomics
206. Life Sciences Fund Amsterdam (LSFA)
207. Life Sciences Partners
208. List Biological Laboratories
209. LIVEYOUNGER Institute
210. Locus Biosciences
211. Longevity Acquisition Corporation (a subsidiary of 4D Pharma)
212. Longwood Fund
213. LUCA Biologics
214. Luina Bio
215. Lundbeckfonden Foundation
216. Lunsford Capital
217. Luxia Scientific
218. MaaT Pharma
219. Macrogen
220. Maruho
221. Massachusetts General Hospital
222. MassChallenge Switzerland
223. MatriSys Bioscience
224. Mayo Clinic
225. MD Anderson Cancer Center
226. MegpPharm 
227. Memorial Sloan Kettering Cancer Center 
228. Merck
229. Metabiomics (a subsidiary of Prescient Medicine)
230. MetaboGen
231. MetaGenoPolis
232. Meteoric Biopharmaceuticals
233. Microba
234. Microbio
235. Microbiome Diagnostic Partners
236. Microbiome Research Centre
237. Microbiotica
238. Micronoma
239. Microviable Therapeutics
240. Mii Fund
241. Mirna Therapeutics
242. Mitchell Cancer Institute, University of South Alabama
243. MyBiotics
244. MyDiagnostics
245. MyMicroZoo
246. Naked Biome
247. Nascita Ventures
248. National Center for Advancing Translational Sciences
249. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
250. National Institutes of Health (NIH) 
251. National Instituteof Allergy and Infectious Diseases (NIAID) 
252. National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
253. National Science Foundation (NSF)
254. Naval Medical Research Center
255. Nestlé Health Science
256. New Ventures
257. Next Act Fund
258. NextBiotics
259. NIZO
260. Notitia Biotechnologies
261. Novo Nordisk
262. Novozymes
263. NuBiyota
264. NYU Langone Health
265. OCA Ventures
266. Olive Tree Capital
267. Ombre
268. One Codex 
269. OneVentures
270. OpenBiome
271. OptiBiotix Health
272. Oracle
273. Orion Fund
274. Osaka University Venture
275. OSbiome
276. Osel
277. Oxford Vacmedix
278. OxThera
279. Pacira Pharmaceuticals (formerly known as SkyePharma)
280. Palex Medical
281. Pangaea Ventures
282. Paris-Saclay University
283. Parkinson's UK
284. Pfizer
285. Phase Genomics
286. Phi Therapeutics
287. PHYZEN
288. Pivotal Life Sciences
289. PivotNorth Capital
290. Plug & Play Ventures
291. Polsky Center
292. Precigen ActoBio™
293. SOLVD Health (formerly known as Prescient Medicine Holdings)
294. Primer Capital
295. ProbioFerm
296. Probiotical
297. Probiotics Australia
298. ProdermIQ
299. Protexin
300. Psomagen
301. Qingdao Institute of Bioenergy and Bioprocess Technology 
302. Qu Biologics
303. Quay Pharma
304. Queen Elizabeth Hospital
305. Quorum Innovations
306. Rambam Health Care Campus
307. Rebiotix
308. Relevance Ventures
309. Resilient Biotics
310. Resphera Biosciences
311. Rev1 Ventures
312. Rise Therapeutics
313. Roche
314. Rocky Mountain Analytical (RMA)
315. RondinX (acquired by BiomX)
316. Roswell Park Comprehensive Cancer Center
317. Sacco
318. S-Biomedic
319. Scanwell Health 
320. SciBac
321. Sciencewerke
322. Scioto Biosciences
323. Second Genome
324. Seed Health
325. Seres Therapeutics
326. Servatus
327. Seventure Partners
328. SeylanMED (acquired by DermBiont)
329. SFA Therapeutics
330. Shanda Group
331. Shoreline Biome
332. Siolta Therapeutics
333. Skive Hospital
334. SNIPR Biome
335. Social Starts
336. Sofimac Innovation
337. SOSV
338. Spanish National Research Council (CSIC)
339. Standard Process
340. Stanford Cancer Institute
341. Stanford Health Care
342. Stanford University School of Medicine
343. Statens Serum Institut
344. Stellate Therapeutics
345. Stora Sköndal
346. Sun Genomics
347. Swiss Integrative Center for Human Health (SICHH)
348. Symberix
349. Symbiosis Pharma
350. Symbiotic Health
351. Symbiotix Biotherapies
352. Synlogic
353. Synthetic Biologics
354. Taiho Ventures
355. Takeda
356. Tech Coast Angels
357. Tencent Holdings
358. Thalys Medical Technology Group 
359. The BioCollective
360. The Craftory
361. The Michael J. Fox Foundation for Parkinson's Research
362. The North Carolina Biotechnology Center
363. The Seerave Foundation
364. TNO
365. Toba Capital
366. Trail Mix Ventures (TMV)
367. Trayer Biotherapeutics
368. UAS Labs
369. uBiome
370. Unilever Ventures
371. Unique Biotech
372. University of Adelaide
373. University of Birmingham
374. University of California San Diego School of Medicine
375. University of Chicago
376. University of Minnesota
377. University of New South Wales
378. University of North Carolina
379. University of Nottingham
380. University of Queensland
381. University of Verona
382. Unpopular Ventures
383. UTokyo Innovation Platform
384. Vaiomer
385. Varinos
386. Vedanta Biosciences
387. Viking Global Investors
388. Viome
389. Virginia Commonwealth University
390. Virtue Group
391. Wacker Biotech
392. Walk-in-Lab
393. Washington Research Foundation
394. Washington University School of Medicine
395. WeGene
396. Wellington Partners
397. Wellmicro
398. Winclove Probiotics
399. Wing Venture Capital
400. WiSEED
401. Xbiome
402. Xycrobe Therapeutics
403. YSOPIA Bioscience
404. Zola Global Investors